{"id":"placebo-to-v260","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL6068498","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"V260 appears to be a vaccine in development by Merck Sharp & Dohme, though the specific antigen target and immunological mechanism are not publicly detailed in widely available sources. As a Phase 3 candidate, it has progressed beyond early-stage testing but the precise mechanism of action remains proprietary or insufficiently disclosed in public literature.","oneSentence":"V260 is an investigational vaccine candidate designed to elicit immune responses against a specific target antigen.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:28:54.213Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06485258","phase":"PHASE1","title":"CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2024-08-06","conditions":"Rotavirus Infections","enrollment":50},{"nctId":"NCT06962904","phase":"PHASE1","title":"CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2025-07-07","conditions":"Rotavirus Infections","enrollment":50},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT05621655","phase":"PHASE2","title":"Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2023-01-08","conditions":"Rotavirus Infections, Rotavirus Gastroenteritis","enrollment":1512},{"nctId":"NCT06350058","phase":"PHASE1","title":"Phase I Clinical Trial of Inactivated Rotavirus Vaccine in a Population Aged 6 Weeks-49 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-08-03","conditions":"Healthy Volunteers","enrollment":375},{"nctId":"NCT02941107","phase":"PHASE4","title":"Optimising Rotavirus Vaccine in Aboriginal Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"Telethon Kids Institute","startDate":"2018-03-27","conditions":"Viral Gastroenteritis Due to Rotavirus","enrollment":1000},{"nctId":"NCT06080906","phase":"PHASE2","title":"Phase II Clinical Trial of the Inactivated Rotavirus Vaccine","status":"UNKNOWN","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2023-10-20","conditions":"Rotavirus Infections, Diarrhea","enrollment":600},{"nctId":"NCT04185545","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity of Rotavirus RV3 Vaccine (Bio Farma) in Neonates","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2020-10-30","conditions":"Rotavirus Gastroenteritis","enrollment":1400},{"nctId":"NCT02145000","phase":"PHASE3","title":"Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis in Niger","status":"COMPLETED","sponsor":"Epicentre","startDate":"2014-06","conditions":"Severe Rotavirus Gastroenteritis","enrollment":6586},{"nctId":"NCT00880698","phase":"PHASE2","title":"Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-12","conditions":"HIV Infection, Rotavirus Infection","enrollment":202},{"nctId":"NCT05037435","phase":"PHASE3","title":"Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.","status":"COMPLETED","sponsor":"Limited Liability Company Pharm Aid","startDate":"2018-06-25","conditions":"Rotavirus Infections, Rotavirus Vaccines","enrollment":40},{"nctId":"NCT00439660","phase":"PHASE1, PHASE2","title":"Dose Escalation Study to Evaluate Oral Rotavirus Vaccine 116E Live Attenuated in Healthy Infants 8 to 20 Weeks Old","status":"COMPLETED","sponsor":"Bharat Biotech International Limited","startDate":"2006-12","conditions":"Diarrhea","enrollment":540},{"nctId":"NCT02992197","phase":"PHASE4","title":"The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and Immunogenicity","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2017-06-12","conditions":"Rotavirus Infection, Vaccine Response Impaired, Vaccine Virus Shedding","enrollment":220},{"nctId":"NCT02646891","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of Trivalent P2-VP8 Subunit Rotavirus Vaccine in Adults, Toddlers and Infants","status":"COMPLETED","sponsor":"PATH","startDate":"2016-02-15","conditions":"Healthy","enrollment":618},{"nctId":"NCT03507738","phase":"PHASE1","title":"Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-07-03","conditions":"Healthy","enrollment":110},{"nctId":"NCT03462108","phase":"PHASE1","title":"Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children & Neonates","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2018-04-09","conditions":"Safety Issues","enrollment":100},{"nctId":"NCT01764256","phase":"PHASE1","title":"A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2012-12","conditions":"Rotavirus Infection","enrollment":48},{"nctId":"NCT01616693","phase":"PHASE4","title":"Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines","status":"COMPLETED","sponsor":"PATH","startDate":"2012-07","conditions":"Immunity to Oral Rotavirus Vaccine, Immunity to Oral Polio Vaccine, Shedding of Oral Rotavirus Vaccine","enrollment":620},{"nctId":"NCT02062385","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-30","conditions":"Rotavirus Gastroenteritis","enrollment":4040},{"nctId":"NCT02584816","phase":"PHASE3","title":"Phase III Study on Rotavirus Vaccine to Evaluate Lot-to-lot Consistency and Interference With Routine UIP Immunization","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2015-11","conditions":"Rotavirus Gastroenteritis","enrollment":1500},{"nctId":"NCT02133690","phase":"PHASE3","title":"A Clinical Trial to Study the Effect and Safety of Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Healthy Indian Infants","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2014-05","conditions":"Rotavirus Gastroenteritis","enrollment":7500},{"nctId":"NCT00420316","phase":"PHASE3","title":"Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-12","conditions":"Infections, Rotavirus","enrollment":1613},{"nctId":"NCT01171963","phase":"PHASE3","title":"Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-29","conditions":"Infections, Rotavirus","enrollment":3340},{"nctId":"NCT00420745","phase":"PHASE3","title":"To Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK's Oral Human Rotavirus Vaccine in Pre-Term Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01-25","conditions":"Infections, Rotavirus","enrollment":1009},{"nctId":"NCT00158756","phase":"PHASE3","title":"Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09-12","conditions":"Hepatitis B","enrollment":308},{"nctId":"NCT02109484","phase":"PHASE1, PHASE2","title":"Phase I/II Descending Age Study of P2VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"PATH","startDate":"2014-03","conditions":"Evaluation of a Rotavirus Vaccine","enrollment":204},{"nctId":"NCT02728869","phase":"PHASE1, PHASE2","title":"Safety, Reactogenicity and Immunogenicity of Heat-stable Rotavirus Vaccine (HSRV) in Adults and Infants","status":"COMPLETED","sponsor":"MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd.","startDate":"2016-06","conditions":"Rotavirus Gastroenteritis","enrollment":100},{"nctId":"NCT01086436","phase":"PHASE1","title":"Study to Evaluate the Safety of Rotarix™ in Chinese Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-03-13","conditions":"Infections, Rotavirus","enrollment":50},{"nctId":"NCT01162590","phase":"PHASE1","title":"Study to Evaluate the Reactogenicity and Safety of Rotarix™ in Chinese Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-03-01","conditions":"Infections, Rotavirus","enrollment":52},{"nctId":"NCT01107587","phase":"PHASE1","title":"Study to Assess the Safety of GSK Biologicals' Liquid Human Rotavirus Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04-13","conditions":"Infections, Rotavirus","enrollment":50},{"nctId":"NCT01511133","phase":"","title":"Serological Response to Porcine Circovirus Type 1 (PCV-1) and PCV-1 DNA in Stools of Infants Following Administration of Rotarix™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04","conditions":"Rotavirus Infection, Evidence of PCV-1 Replication and/or Immune Response to the PCV-1 in HRV Vaccinated Infants","enrollment":1},{"nctId":"NCT00718237","phase":"PHASE3","title":"Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Rotavirus, Gastroenteritis","enrollment":762},{"nctId":"NCT00169455","phase":"PHASE3","title":"Assess the Immunogenicity of the Human Rotavirus (HRV) Vaccine After Reconstitution Without Buffering Agent; & Evaluate the Immunogenicity, Reactogenicity & Safety of the Vaccine After Storage for 7 d at 37°C Following 2 Doses in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03","conditions":"Rotavirus Gastroenteritis","enrollment":450},{"nctId":"NCT00329745","phase":"PHASE3","title":"Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-028, 029 or 030 (NCT00197210)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01","conditions":"Infections, Rotavirus","enrollment":8687},{"nctId":"NCT00953056","phase":"PHASE1","title":"A Study of V260 in Healthy Chinese Adults, Children and Infants (V260-028)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09","conditions":"Rotavirus Gastroenteritis","enrollment":144},{"nctId":"NCT00258154","phase":"PHASE3","title":"V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-02","conditions":"Rotavirus Disease","enrollment":403},{"nctId":"NCT00092456","phase":"PHASE3","title":"Consistency Lots Vaccine Study (V260-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-05","conditions":"Rotavirus Infections","enrollment":793},{"nctId":"NCT00090233","phase":"PHASE3","title":"Rotavirus Efficacy and Safety Trial (REST)(V260-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-01","conditions":"Rotavirus Infections","enrollment":69274},{"nctId":"NCT00092443","phase":"PHASE3","title":"Dose Confirmation Efficacy Study (V260-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-09","conditions":"Rotavirus Infections","enrollment":1312},{"nctId":"NCT02153333","phase":"","title":"Serologic Response to Porcine Circovirus Type 1 (PCV-1) in Infants Following Administration of Rotarix™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02","conditions":"Infections, Rotavirus","enrollment":1},{"nctId":"NCT00166517","phase":"PHASE3","title":"V260 Registration Study (V260-013)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-08","conditions":"Rotavirus","enrollment":178},{"nctId":"NCT01542320","phase":"NA","title":"Effect of Probiotic Supplementation on Immune Function in Healthy Infants","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-03","conditions":"Inflammation","enrollment":15},{"nctId":"NCT01305109","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E","status":"UNKNOWN","sponsor":"Bharat Biotech International Limited","startDate":"2011-03","conditions":"Viral Gastroenteritis Due to Rotavirus","enrollment":6800},{"nctId":"NCT01091298","phase":"PHASE1","title":"A Study to Evaluate the Safety of Tetravalent Rotavirus Vaccine in Healthy Indian Adult Male Volunteers","status":"COMPLETED","sponsor":"Shantha Biotechnics Limited","startDate":"2010-04","conditions":"Rotavirus Gastroenteritis","enrollment":20},{"nctId":"NCT01061658","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of the Tetravalent Rotavirus Vaccine","status":"UNKNOWN","sponsor":"Shantha Biotechnics Limited","startDate":"2010-07","conditions":"Rotavirus Gastroenteritis","enrollment":90},{"nctId":"NCT00757926","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of the Recombinant Human Bovine Reassortant Rotavirus Vaccine in Healthy Indian Infants","status":"WITHDRAWN","sponsor":"Shantha Biotechnics Limited","startDate":"2009-09","conditions":"Rotavirus Infections","enrollment":240},{"nctId":"NCT00280111","phase":"PHASE1","title":"Safety and Immunogenicity Study of Live Attenuated Indian Rotavirus Vaccine Candidate Strains 116E and I321 in Infants","status":"COMPLETED","sponsor":"Society for Applied Studies","startDate":"2005-01","conditions":"Rotavirus Infections","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to V260","genericName":"Placebo to V260","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}